



Clinical trial results:

A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naïve and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2011-001323-21 |
| Trial protocol | DE AT PL |
| Global end of trial date | 13 January 2014 |

Results information

| | |
|--------------------------------|--|
| Result version number | v2 (current) |
| This version publication date | 13 July 2016 |
| First version publication date | 07 August 2015 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set Update required to address issues related to the EudraCT System bug, that necessitated the review and Quality check of results posting and to ensure data accuracy |

Trial information

Trial identification

| | |
|-----------------------|--------------|
| Sponsor protocol code | VX11-950-114 |
|-----------------------|--------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01459913 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Vertex Pharmaceuticals Incorporated |
| Sponsor organisation address | 50 Northern Avenue, Boston, Massachusetts, United States, 02210-1862 |
| Public contact | Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com |
| Scientific contact | Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 24 February 2014 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 13 January 2014 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of a 12-week regimen of telaprevir, pegylated interferon (Peg-IFN), and ribavirin (RBV) in treatment-naïve and prior relapser subjects with genotype 1 chronic hepatitis C (CHC) and interleukin-28B (IL28B) CC genotype

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 11 November 2011 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Austria: 25 |
| Country: Number of subjects enrolled | Germany: 11 |
| Country: Number of subjects enrolled | Canada: 28 |
| Country: Number of subjects enrolled | Poland: 19 |
| Country: Number of subjects enrolled | Israel: 18 |
| Country: Number of subjects enrolled | United States: 138 |
| Worldwide total number of subjects | 239 |
| EEA total number of subjects | 55 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|-----|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 228 |
| From 65 to 84 years | 11 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects received telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a)/ ribavirin (RBV). Planned duration of telaprevir treatment was 12 weeks. Minimum planned duration of Peg-IFN-alfa-2a/RBV treatment was 12 weeks; however, was dependent on virologic response during initial 12 weeks of telaprevir plus Peg-IFN-alfa-2a/RBV.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--|
| Are arms mutually exclusive? | Yes |
| Arm title | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) |

Arm description:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Telaprevir |
| Investigational medicinal product code | VX-950 |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks.

| | |
|--|--|
| Investigational medicinal product name | Pegylated interferon alfa 2a |
| Investigational medicinal product code | |
| Other name | Pegasys ®, Peg-INF |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week).

| | |
|--|-----------|
| Investigational medicinal product name | Ribavirin |
| Investigational medicinal product code | |
| Other name | Copegus ® |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Ribavirin (RBV) tablet twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks.

| | |
|------------------|---|
| Arm title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|------------------|---|

Arm description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Telaprevir |
| Investigational medicinal product code | VX-950 |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Telaprevir 1125 mg tablet twice daily for 12 weeks.

| | |
|--|--|
| Investigational medicinal product name | Peg-IFN-alfa-2a |
| Investigational medicinal product code | |
| Other name | Pegasys ®, Peg-INF |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Peg-IFN-alfa-2a 180 mcg/week.

| | |
|--|-----------|
| Investigational medicinal product name | Ribavirin |
| Investigational medicinal product code | |
| Other name | Copegus ® |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

RBV tablet twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks.

| | |
|------------------|---|
| Arm title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|------------------|---|

Arm description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Telaprevir |
| Investigational medicinal product code | VX-950 |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Telaprevir 1125 mg tablet twice daily for 12 weeks.

| | |
|--|--|
| Investigational medicinal product name | Pegylated interferon alfa 2a |
| Investigational medicinal product code | |
| Other name | Pegasys ®, Peg-INF |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Peg-IFN-alfa-2a 180 mcg/week .

| | |
|--|-----------|
| Investigational medicinal product name | Ribavirin |
| Investigational medicinal product code | |
| Other name | Copegus ® |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

RBV tablet twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks.

| | |
|------------------|---|
| Arm title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|------------------|---|

Arm description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Telaprevir |
| Investigational medicinal product code | VX-950 |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Telaprevir 1125 mg tablet twice daily for 12 weeks.

| | |
|--|--|
| Investigational medicinal product name | Pegylated interferon alfa 2a |
| Investigational medicinal product code | |
| Other name | Pegasys ®, Peg-INF |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Peg-IFN-alfa-2a 180 mcg/week.

| | |
|--|-----------|
| Investigational medicinal product name | Ribavirin |
| Investigational medicinal product code | |
| Other name | Copegus ® |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

RBV tablet twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 48 weeks.

| Number of subjects in period 1 | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|---------------------------------------|---|--|--|
| Started | 106 | 52 | 19 |
| Completed | 65 | 32 | 6 |
| Not completed | 41 | 20 | 13 |
| Consent withdrawn by subject | 4 | - | - |
| Physician decision | - | 1 | - |
| Adverse Event | - | - | - |

| | | | |
|---------------------------------|----|----|---|
| Death | - | - | - |
| Did Not Meet Inclusion Criteria | - | - | - |
| Unspecified | - | - | 3 |
| Study Terminated by Sponsor | 30 | 15 | 9 |
| Lost to follow-up | 7 | 4 | 1 |
| Non- Compliance | - | - | - |

| Number of subjects in period 1 | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|---------------------------------------|---|
| Started | 62 |
| Completed | 29 |
| Not completed | 33 |
| Consent withdrawn by subject | 5 |
| Physician decision | - |
| Adverse Event | 3 |
| Death | 1 |
| Did Not Meet Inclusion Criteria | 1 |
| Unspecified | 1 |
| Study Terminated by Sponsor | 11 |
| Lost to follow-up | 8 |
| Non- Compliance | 3 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) |
|-----------------------|--|

Reporting group description:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

| Reporting group values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|------------------------|--|---|---|
| Number of subjects | 106 | 52 | 19 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|---------|---------|-------|
| Age continuous | | | |
| Number subjects analysed for this parameter are 106, 52, 19 and 61 respectively. | | | |
| Units: years | | | |
| arithmetic mean | 46.1 | 44.8 | 54.4 |
| standard deviation | ± 12.82 | ± 12.89 | ± 8.7 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 39 | 16 | 11 |
| Male | 67 | 36 | 8 |

| Reporting group values | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) | Total | |
|--|---|-------|--|
| Number of subjects | 62 | 239 | |
| Age categorical Units: Subjects | | | |
| Age continuous | | | |
| Number subjects analysed for this parameter are 106, 52, 19 and 61 respectively. | | | |
| Units: years arithmetic mean standard deviation | 49.8 ± 10.56 | - | |
| Gender categorical Units: Subjects | | | |
| Female | 29 | 95 | |
| Male | 33 | 144 | |

End points

End points reporting groups

| | |
|-----------------------|--|
| Reporting group title | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) |
|-----------------------|--|

Reporting group description:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\geq) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing \geq 75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing \geq 75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing \geq 75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

| | |
|----------------------------|---|
| Subject analysis set title | Telaprevir+Peg-IFN-alfa-2a, RBV (Total) |
|----------------------------|---|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

All subjects who received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing \geq 75 kg, up to 48 weeks.

Primary: Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

| | |
|-----------------|---|
| End point title | Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12) ^{[1][2]} |
|-----------------|---|

End point description:

SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. Full Analysis (FA) Set was used.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

12 weeks after last planned dose of study drug (up to Week 36)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics was planned for this study.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | | |
|-------------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 | 52 | | |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | 88.7 | 96.2 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)

| | |
|-----------------|--|
| End point title | Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4) ^[3] |
|-----------------|--|

End point description:

SVR4 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 4 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. FA Set was used.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

4 weeks after last planned dose of study drug (up to Week 28)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | | |
|-------------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 | 52 | | |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | 89.6 | 98.1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

| | |
|-----------------|--|
| End point title | Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24) ^[4] |
|-----------------|--|

End point description:

SVR24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. FA Set was used.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 weeks after last planned dose of study drug (up to Week 48)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | | |
|-------------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 | 52 | | |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | 85.8 | 92.3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)

| | |
|-----------------|--|
| End point title | Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72) ^[5] |
|-----------------|--|

End point description:

SVR72 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 72. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. FA Set was used. Here number of subjects analyzed = subjects who were evaluable for this measure. Subjects who did not have the SVR72 assessment because they discontinued the study due to 'Study Terminated by the Sponsor' are excluded from this analysis.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 72

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)"

reporting groups.

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | | |
|-------------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 76 | 37 | | |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | 72.4 | 86.5 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Viral Relapse

| | |
|---|--|
| End point title | Percentage of Subjects With Viral Relapse ^[6] |
| End point description: | |
| Viral relapse was defined as having detectable HCV RNA during antiviral follow-up in subjects who had HCV RNA less than (<) lower limit of quantification (LLOQ) at end of treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The LLOQ was 25 IU/mL and the lower limit of detection was 10 IU/mL. FA Set was used. | |
| End point type | Secondary |
| End point timeframe: | |
| After last dose of study drug up to 4 weeks (up to Week 28), 12 weeks (up to Week 36), 24 weeks (up to Week 48) antiviral follow-up | |

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | | |
|-------------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 | 52 | | |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | | | | |
| 4 Weeks | 1.9 | 0 | | |
| 12 Weeks | 7.5 | 0 | | |
| 24 Weeks | 10.4 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With On-Treatment Virologic Failure

| | |
|--|--|
| End point title | Percentage of Subjects With On-Treatment Virologic Failure |
| End point description: On-treatment virologic failure was defined as subjects who met futility (as per investigator discretion) or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). This outcome was planned to be assessed in all reporting groups and results were to be reported for total arm as well. FA Set was used. | |
| End point type | Secondary |
| End point timeframe: Baseline up to Week 48 | |

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|-------------------------------|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 106 | 52 | 19 | 61 |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | 0 | 0 | 0 | 3.3 |

| End point values | Telaprevir+Peg-IFN-alfa-2a, RBV (Total) | | | |
|-------------------------------|---|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 238 | | | |
| Units: Percentage of Subjects | | | | |
| number (not applicable) | 0.8 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Rapid Viral Response (RVR)

| | |
|--|---|
| End point title | Number of Subjects With Rapid Viral Response (RVR) ^[7] |
| End point description: The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment. FA Set was used. | |
| End point type | Secondary |
| End point timeframe: Week 4 | |

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | | |
|-----------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 | 52 | | |
| Units: Subjects | 106 | 52 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Extended Rapid Viral Response (eRVR)

| | |
|-----------------|---|
| End point title | Number of Subjects With Extended Rapid Viral Response (eRVR) ^[8] |
|-----------------|---|

End point description:

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment. FA Set was used.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 4 and Week 12

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | | |
|-----------------------------|---|---|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 | 52 | | |
| Units: Subjects | 105 | 51 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Adverse Events (AEs) and Serious Adverse

Events (SAEs)

| | |
|-----------------|--|
| End point title | Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) |
|-----------------|--|

End point description:

AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study. Safety set included all subjects who received at least 1 dose of study drug.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 48

| End point values | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|-----------------------------|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 106 | 52 | 19 | 62 |
| Units: Subjects | | | | |
| AEs | 104 | 51 | 19 | 61 |
| SAEs | 5 | 4 | 3 | 13 |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 48

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 16.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned, and did not receive any further treatment.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

| | |
|-----------------------|---|
| Reporting group title | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|-----------------------|---|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

| | |
|-----------------------|--|
| Reporting group title | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|-----------------------|--|

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

| Serious adverse events | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 4 / 52 (7.69%) | 3 / 19 (15.79%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--|-----------------|----------------|-----------------|
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Syncope | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 3 / 52 (5.77%) | 2 / 19 (10.53%) |
| occurrences causally related to treatment / all | 3 / 3 | 3 / 3 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest pain | | | |

| | | | |
|--|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Colitis microscopic | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis chronic | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|----------------|----------------|
| Skin and subcutaneous tissue disorders | | | |
| Drug reaction with eosinophilia and systemic symptoms | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Renal failure acute | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess oral | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perirectal abscess | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------|---|--|--|
| Serious adverse events | Telaprevir 12 Wk +Peg-IFN-alfa- 2a,RBV 48 Wk (Non | | |
|-------------------------------|---|--|--|

| | Randomized) | | |
|--|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 13 / 62 (20.97%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypotension | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thrombosis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Syncope | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 7 / 62 (11.29%) | | |
| occurrences causally related to treatment / all | 7 / 7 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chest pain | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Colitis microscopic | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancreatitis chronic | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|----------------|--|--|
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Drug reaction with eosinophilia and systemic symptoms | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Renal failure acute | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Pneumonia | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences causally related to treatment / all | 2 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Abscess oral | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Perirectal abscess | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 104 / 106 (98.11%) | 51 / 52 (98.08%) | 19 / 19 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Vascular disorders | | | |
| Pallor | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Circulatory collapse | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |

| | | | |
|--|-------------------|------------------|------------------|
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypertension | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral coldness | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vascular pain | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 55 / 106 (51.89%) | 25 / 52 (48.08%) | 12 / 19 (63.16%) |
| occurrences (all) | 59 | 25 | 13 |
| Pyrexia | | | |
| subjects affected / exposed | 26 / 106 (24.53%) | 13 / 52 (25.00%) | 4 / 19 (21.05%) |
| occurrences (all) | 28 | 14 | 4 |
| Influenza like illness | | | |
| subjects affected / exposed | 28 / 106 (26.42%) | 10 / 52 (19.23%) | 8 / 19 (42.11%) |
| occurrences (all) | 29 | 10 | 8 |
| Asthenia | | | |
| subjects affected / exposed | 14 / 106 (13.21%) | 8 / 52 (15.38%) | 3 / 19 (15.79%) |
| occurrences (all) | 14 | 9 | 3 |
| Irritability | | | |
| subjects affected / exposed | 9 / 106 (8.49%) | 7 / 52 (13.46%) | 2 / 19 (10.53%) |
| occurrences (all) | 9 | 8 | 2 |
| Chills | | | |
| subjects affected / exposed | 6 / 106 (5.66%) | 6 / 52 (11.54%) | 0 / 19 (0.00%) |
| occurrences (all) | 6 | 6 | 0 |
| Injection site erythema | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 5 / 106 (4.72%) | 4 / 52 (7.69%) | 0 / 19 (0.00%) |
| occurrences (all) | 5 | 4 | 0 |
| Pain | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 3 / 52 (5.77%) | 1 / 19 (5.26%) |
| occurrences (all) | 5 | 3 | 1 |
| Malaise | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 1 | 1 |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 4 / 52 (7.69%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 4 | 1 |
| Injection site reaction | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 2 / 52 (3.85%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 2 | 1 |
| Injection site rash | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 4 / 52 (7.69%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Injection site pruritus | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 2 | 1 |
| Local swelling | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Thirst | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Feeling abnormal | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Injection site bruising | | | |

| | | | |
|--|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Enanthema | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Feeling cold | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Feeling hot | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Temperature intolerance | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Immune system disorders | | | |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 4 / 52 (7.69%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Reproductive system and breast disorders | | | |
| Menorrhagia | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Metrorrhagia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Amenorrhoea | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Erectile dysfunction | | | |

| | | | |
|---|-------------------|------------------|-----------------|
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Menstrual disorder | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pruritus genital | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scrotal erythema | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scrotal pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 18 / 106 (16.98%) | 11 / 52 (21.15%) | 5 / 19 (26.32%) |
| occurrences (all) | 19 | 12 | 5 |
| Cough | | | |
| subjects affected / exposed | 9 / 106 (8.49%) | 5 / 52 (9.62%) | 0 / 19 (0.00%) |
| occurrences (all) | 9 | 5 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 7 / 106 (6.60%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 7 | 1 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 5 | 0 | 1 |
| Epistaxis | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 3 | 1 | 1 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 2 / 19 (10.53%) |
| occurrences (all) | 0 | 1 | 2 |
| Rhinorrhoea | | | |

| | | | |
|------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 1 | 1 |
| Productive cough | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Sneezing | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal discomfort | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal disorder | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal dryness | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal inflammation | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal mucosal disorder | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oropharyngeal discomfort | | | |

| | | | |
|-----------------------------|-------------------|------------------|-----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Painful respiration | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Pharyngeal oedema | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rales | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiration abnormal | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 22 / 106 (20.75%) | 11 / 52 (21.15%) | 6 / 19 (31.58%) |
| occurrences (all) | 22 | 12 | 6 |
| Depression | | | |
| subjects affected / exposed | 12 / 106 (11.32%) | 8 / 52 (15.38%) | 4 / 19 (21.05%) |
| occurrences (all) | 12 | 8 | 4 |
| Anxiety | | | |
| subjects affected / exposed | 6 / 106 (5.66%) | 2 / 52 (3.85%) | 2 / 19 (10.53%) |
| occurrences (all) | 6 | 2 | 2 |
| Depressed mood | | | |
| subjects affected / exposed | 4 / 106 (3.77%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Mood swings | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Affect lability | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| Agitation | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anger | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Mood altered | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Apathy | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Drug dependence | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Emotional disorder | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Initial insomnia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nervousness | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Aggression | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| Disorientation | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Libido decreased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Loss of libido | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Personality disorder | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| Weight decreased | | | |
| subjects affected / exposed | 8 / 106 (7.55%) | 2 / 52 (3.85%) | 2 / 19 (10.53%) |
| occurrences (all) | 8 | 2 | 2 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 3 | 1 | 2 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 2 / 19 (10.53%) |
| occurrences (all) | 2 | 0 | 2 |
| Amylase increased | | | |

| | | | |
|---|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Blood urine present | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood calcium decreased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood creatinine increased | | | |

| | | | |
|--|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Body temperature increased | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Electrocardiogram ST-T change | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eosinophil count increased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematocrit decreased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobin increased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Liver function test abnormal | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory rate increased | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |

| | | | |
|--------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Laceration | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Scratch | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Arthropod bite | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Excoriation | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 1 / 52 (1.92%) | 2 / 19 (10.53%) |
| occurrences (all) | 3 | 1 | 2 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Arrhythmia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| supraventricular Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Supraventricular extrasystoles | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|-------------------|------------------|-----------------|
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 30 / 106 (28.30%) | 16 / 52 (30.77%) | 5 / 19 (26.32%) |
| occurrences (all) | 30 | 16 | 5 |
| Dizziness | | | |
| subjects affected / exposed | 17 / 106 (16.04%) | 6 / 52 (11.54%) | 6 / 19 (31.58%) |
| occurrences (all) | 18 | 8 | 6 |
| Dysgeusia | | | |
| subjects affected / exposed | 13 / 106 (12.26%) | 2 / 52 (3.85%) | 2 / 19 (10.53%) |
| occurrences (all) | 13 | 2 | 2 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 5 / 52 (9.62%) | 0 / 19 (0.00%) |
| occurrences (all) | 4 | 6 | 0 |
| Migraine | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 3 / 52 (5.77%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 3 | 1 |
| Disturbance in attention | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 1 | 1 |
| Paraesthesia | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lethargy | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Syncope | | | |

| | | | |
|--------------------------------------|-------------------|------------------|------------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cognitive disorder | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dizziness exertional | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Drooling | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Mental impairment | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Parosmia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 42 / 106 (39.62%) | 22 / 52 (42.31%) | 10 / 19 (52.63%) |
| occurrences (all) | 46 | 25 | 14 |

| | | | |
|------------------------------|-----------------|----------------|-----------------|
| Neutropenia | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 4 / 52 (7.69%) | 4 / 19 (21.05%) |
| occurrences (all) | 6 | 4 | 5 |
| Leukopenia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 1 | 1 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 3 | 0 | 1 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pancytopenia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 4 / 106 (3.77%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Ear pruritus | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Ear discomfort | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Ear pain | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperacusis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoacusis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otorrhoea | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorders | | | |
| Vision blurred | | | |
| subjects affected / exposed | 8 / 106 (7.55%) | 2 / 52 (3.85%) | 3 / 19 (15.79%) |
| occurrences (all) | 8 | 3 | 3 |
| Dry eye | | | |
| subjects affected / exposed | 4 / 106 (3.77%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| Retinal exudates | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abnormal sensation in eye | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Conjunctivitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye haemorrhage | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular discomfort | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Retinal haemorrhage | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| photophobia | | | |
| subjects affected / exposed | 6 / 106 (5.66%) | 3 / 52 (5.77%) | 0 / 19 (0.00%) |
| occurrences (all) | 6 | 3 | 0 |

| | | | |
|-----------------------------|-------------------|------------------|------------------|
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 49 / 106 (46.23%) | 19 / 52 (36.54%) | 13 / 19 (68.42%) |
| occurrences (all) | 51 | 22 | 15 |
| Diarrhoea | | | |
| subjects affected / exposed | 19 / 106 (17.92%) | 6 / 52 (11.54%) | 6 / 19 (31.58%) |
| occurrences (all) | 21 | 6 | 6 |
| Vomiting | | | |
| subjects affected / exposed | 17 / 106 (16.04%) | 6 / 52 (11.54%) | 6 / 19 (31.58%) |
| occurrences (all) | 18 | 7 | 6 |
| Anorectal discomfort | | | |
| subjects affected / exposed | 22 / 106 (20.75%) | 9 / 52 (17.31%) | 3 / 19 (15.79%) |
| occurrences (all) | 22 | 9 | 3 |
| Anal pruritus | | | |
| subjects affected / exposed | 10 / 106 (9.43%) | 8 / 52 (15.38%) | 3 / 19 (15.79%) |
| occurrences (all) | 11 | 10 | 3 |
| Haemorrhoids | | | |
| subjects affected / exposed | 8 / 106 (7.55%) | 4 / 52 (7.69%) | 1 / 19 (5.26%) |
| occurrences (all) | 8 | 4 | 1 |
| Dry mouth | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 3 / 52 (5.77%) | 3 / 19 (15.79%) |
| occurrences (all) | 5 | 3 | 3 |
| Dyspepsia | | | |
| subjects affected / exposed | 9 / 106 (8.49%) | 2 / 52 (3.85%) | 1 / 19 (5.26%) |
| occurrences (all) | 9 | 2 | 1 |
| Proctalgia | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 4 / 52 (7.69%) | 0 / 19 (0.00%) |
| occurrences (all) | 5 | 4 | 0 |
| Constipation | | | |
| subjects affected / exposed | 4 / 106 (3.77%) | 1 / 52 (1.92%) | 3 / 19 (15.79%) |
| occurrences (all) | 4 | 1 | 3 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Abdominal pain | | | |

| | | | |
|----------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 3 / 106 (2.83%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Aphthous stomatitis | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 2 / 52 (3.85%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 2 | 1 |
| Stomatitis | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 1 | 1 |
| Abdominal discomfort | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gingival bleeding | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 1 | 1 |
| Anal haemorrhage | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 1 | 1 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Glossodynia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Proctitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Retching | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal fissure | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bowel movement irregularity | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Duodenal ulcer | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eructation | | | |

| | | | |
|------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Faeces pale | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Frequent bowel movements | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal motility disorder | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperchlorhydria | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lip pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oral discomfort | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Perianal erythema | | | |

| | | | |
|--|-------------------|------------------|-----------------|
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Sensitivity of teeth | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Steatorrhoea | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Swollen tongue | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tongue coated | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tongue disorder | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth impacted | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Periportal oedema | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Pruritus | | | |
| subjects affected / exposed | 44 / 106 (41.51%) | 17 / 52 (32.69%) | 8 / 19 (42.11%) |
| occurrences (all) | 52 | 18 | 11 |
| Rash | | | |
| subjects affected / exposed | 31 / 106 (29.25%) | 15 / 52 (28.85%) | 9 / 19 (47.37%) |
| occurrences (all) | 38 | 22 | 16 |
| Alopecia | | | |

| | | | |
|-----------------------------|-------------------|------------------|-----------------|
| subjects affected / exposed | 13 / 106 (12.26%) | 11 / 52 (21.15%) | 4 / 19 (21.05%) |
| occurrences (all) | 13 | 11 | 4 |
| Dry skin | | | |
| subjects affected / exposed | 11 / 106 (10.38%) | 11 / 52 (21.15%) | 6 / 19 (31.58%) |
| occurrences (all) | 11 | 11 | 6 |
| Pruritus generalised | | | |
| subjects affected / exposed | 4 / 106 (3.77%) | 3 / 52 (5.77%) | 3 / 19 (15.79%) |
| occurrences (all) | 4 | 3 | 5 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 2 / 52 (3.85%) | 3 / 19 (15.79%) |
| occurrences (all) | 9 | 2 | 4 |
| Rash papular | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 1 / 52 (1.92%) | 4 / 19 (21.05%) |
| occurrences (all) | 5 | 2 | 7 |
| Rash erythematous | | | |
| subjects affected / exposed | 4 / 106 (3.77%) | 1 / 52 (1.92%) | 2 / 19 (10.53%) |
| occurrences (all) | 6 | 1 | 3 |
| Rash pruritic | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 2 / 52 (3.85%) | 2 / 19 (10.53%) |
| occurrences (all) | 2 | 4 | 3 |
| Dermatitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Rash generalised | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 2 | 1 |
| Swelling face | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 2 / 19 (10.53%) |
| occurrences (all) | 2 | 0 | 2 |
| Erythema | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 1 | 1 |
| Night sweats | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Psoriasis | | | |

| | | | |
|---|-----------------|----------------|----------------|
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 1 | 1 |
| Drug eruption | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Drug reaction with eosinophilia and systemic symptoms | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hair growth abnormal | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hair texture abnormal | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|-----------------|----------------|----------------|
| Onychoclasia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Purpura | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash follicular | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash vesicular | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scab | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Seborrhoea | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Seborrhoeic dermatitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin burning sensation | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin exfoliation | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Stasis dermatitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Telangiectasia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Renal and urinary disorders | | | |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 9 / 106 (8.49%) | 7 / 52 (13.46%) | 2 / 19 (10.53%) |
| occurrences (all) | 12 | 7 | 3 |
| Myalgia | | | |
| subjects affected / exposed | 6 / 106 (5.66%) | 7 / 52 (13.46%) | 0 / 19 (0.00%) |
| occurrences (all) | 6 | 7 | 0 |
| Back pain | | | |
| subjects affected / exposed | 6 / 106 (5.66%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 6 | 2 | 0 |
| Muscle spasms | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 3 / 106 (2.83%) | 4 / 52 (7.69%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 5 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 2 / 52 (3.85%) | 1 / 19 (5.26%) |
| occurrences (all) | 3 | 2 | 2 |
| Joint swelling | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 2 / 19 (10.53%) |
| occurrences (all) | 1 | 1 | 2 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Plantar fasciitis | | | |

| | | | |
|-----------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal pain | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infections and infestations | | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 5 / 106 (4.72%) | 1 / 52 (1.92%) | 2 / 19 (10.53%) |
| occurrences (all) | 6 | 1 | 3 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 106 (1.89%) | 1 / 52 (1.92%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 1 | 1 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 3 / 52 (5.77%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 3 | 1 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 3 / 52 (5.77%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 2 / 52 (3.85%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| Skin infection | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vulvovaginal candidiasis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis infected | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Genital herpes | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gingivitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes pharyngitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Parotitis | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash pustular | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------|-------------------|-----------------|-----------------|
| Rhinitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scrotal abscess | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea cruris | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vulvovaginal mycotic infection | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 21 / 106 (19.81%) | 6 / 52 (11.54%) | 4 / 19 (21.05%) |
| occurrences (all) | 21 | 7 | 4 |
| Dehydration | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abnormal loss of weight | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gout | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperuricaemia | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 52 (1.92%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 52 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|--|--|--|
| Non-serious adverse events | Telaprevir 12 Wk +Peg-IFN-alfa- 2a,RBV 48 Wk (Non Randomized) | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 61 / 62 (98.39%) | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vascular disorders | | | |
| Pallor | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Circulatory collapse | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Hot flush | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|--|------------------|--|--|
| Hypotension | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Orthostatic hypertension | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Peripheral coldness | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vascular pain | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 26 / 62 (41.94%) | | |
| occurrences (all) | 29 | | |
| Pyrexia | | | |
| subjects affected / exposed | 15 / 62 (24.19%) | | |
| occurrences (all) | 15 | | |
| Influenza like illness | | | |
| subjects affected / exposed | 9 / 62 (14.52%) | | |
| occurrences (all) | 9 | | |
| Asthenia | | | |
| subjects affected / exposed | 13 / 62 (20.97%) | | |
| occurrences (all) | 16 | | |
| Irritability | | | |
| subjects affected / exposed | 9 / 62 (14.52%) | | |
| occurrences (all) | 9 | | |
| Chills | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 9 / 62 (14.52%) | | |
| occurrences (all) | 9 | | |
| Injection site erythema | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Pain | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Malaise | | | |
| subjects affected / exposed | 5 / 62 (8.06%) | | |
| occurrences (all) | 5 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Injection site reaction | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site rash | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site pruritus | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Local swelling | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Thirst | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Feeling abnormal | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site bruising | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Enanthema | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Feeling hot | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Temperature intolerance | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Immune system disorders | | | |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Reproductive system and breast disorders | | | |
| Menorrhagia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metrorrhagia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Amenorrhoea | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Erectile dysfunction | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Menstrual disorder | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pruritus genital | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Scrotal erythema | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Scrotal pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 9 / 62 (14.52%) | | |
| occurrences (all) | 13 | | |
| Cough | | | |
| subjects affected / exposed | 9 / 62 (14.52%) | | |
| occurrences (all) | 11 | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Epistaxis | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Nasal congestion | | | |

| | | | |
|------------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Productive cough | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sneezing | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hiccups | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Nasal discomfort | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasal disorder | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasal dryness | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasal inflammation | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasal mucosal disorder | | | |

| | | | |
|-----------------------------|------------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oropharyngeal discomfort | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Painful respiration | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Paranasal sinus discomfort | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pharyngeal oedema | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rales | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiration abnormal | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 12 / 62 (19.35%) | | |
| occurrences (all) | 12 | | |
| Depression | | | |
| subjects affected / exposed | 10 / 62 (16.13%) | | |
| occurrences (all) | 10 | | |
| Anxiety | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Depressed mood | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Mood swings | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |

| | | | |
|-----------------------------|----------------|--|--|
| Affect lability | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Agitation | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Anger | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Mood altered | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Sleep disorder | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Apathy | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Drug dependence | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Emotional disorder | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Initial insomnia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Nervousness | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Restlessness | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Aggression | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|-----------------------------|----------------|--|--|
| Confusional state | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Disorientation | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Libido decreased | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Loss of libido | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Personality disorder | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Investigations | | | |
| Weight decreased | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Blood uric acid increased | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Blood pressure increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Platelet count decreased | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Amylase increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Blood potassium decreased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Blood calcium decreased | | | |

| | | | |
|----------------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Body temperature increased | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Electrocardiogram ST-T change | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eosinophil count increased | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Haematocrit decreased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Haemoglobin increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 2 | | |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Respiratory rate increased | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Injury, poisoning and procedural | | | |

| | | | |
|--------------------------------------|----------------|--|--|
| complications | | | |
| Contusion | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Laceration | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Scratch | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Arthropod bite | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Excoriation | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Tachycardia | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Arrhythmia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| supraventricular Atrial fibrillation | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Supraventricular extrasystoles | | | |

| | | | |
|-----------------------------|------------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 17 / 62 (27.42%) | | |
| occurrences (all) | 17 | | |
| Dizziness | | | |
| subjects affected / exposed | 14 / 62 (22.58%) | | |
| occurrences (all) | 15 | | |
| Dysgeusia | | | |
| subjects affected / exposed | 5 / 62 (8.06%) | | |
| occurrences (all) | 5 | | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Migraine | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Disturbance in attention | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyperaesthesia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Somnolence | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Lethargy | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|--------------------------------------|----------------|--|--|
| Syncope | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cognitive disorder | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dizziness exertional | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Drooling | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Mental impairment | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Parosmia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Sciatica | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Tremor | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|------------------------------|------------------|--|--|
| subjects affected / exposed | 20 / 62 (32.26%) | | |
| occurrences (all) | 23 | | |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 2 | | |
| Leukopenia | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Lymphopenia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Tinnitus | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Ear pruritus | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear discomfort | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|---|--|--|--|
| <p>Ear pain</p> <p>subjects affected / exposed</p> <p>0 / 62 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> | | | |
| <p>Hyperacusis</p> <p>subjects affected / exposed</p> <p>0 / 62 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> | | | |
| <p>Hypoacusis</p> <p>subjects affected / exposed</p> <p>1 / 62 (1.61%)</p> <p>occurrences (all)</p> <p>1</p> | | | |
| <p>Otorrhoea</p> <p>subjects affected / exposed</p> <p>0 / 62 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> | | | |
| <p>Eye disorders</p> <p>Vision blurred</p> <p>subjects affected / exposed</p> <p>2 / 62 (3.23%)</p> <p>occurrences (all)</p> <p>2</p> | | | |
| <p>Dry eye</p> <p>subjects affected / exposed</p> <p>4 / 62 (6.45%)</p> <p>occurrences (all)</p> <p>4</p> | | | |
| <p>Eye pruritus</p> <p>subjects affected / exposed</p> <p>1 / 62 (1.61%)</p> <p>occurrences (all)</p> <p>1</p> | | | |
| <p>Ocular hyperaemia</p> <p>subjects affected / exposed</p> <p>2 / 62 (3.23%)</p> <p>occurrences (all)</p> <p>2</p> | | | |
| <p>Visual impairment</p> <p>subjects affected / exposed</p> <p>1 / 62 (1.61%)</p> <p>occurrences (all)</p> <p>1</p> | | | |
| <p>Diplopia</p> <p>subjects affected / exposed</p> <p>1 / 62 (1.61%)</p> <p>occurrences (all)</p> <p>1</p> | | | |
| <p>Eye irritation</p> <p>subjects affected / exposed</p> <p>1 / 62 (1.61%)</p> <p>occurrences (all)</p> <p>1</p> | | | |
| <p>Eye pain</p> | | | |

| | | | |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Retinal exudates | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Abnormal sensation in eye | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye haemorrhage | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Eyelid oedema | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Ocular discomfort | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Retinal haemorrhage | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vitreous floaters | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| photophobia | | | |

| | | | |
|-----------------------------|------------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 33 / 62 (53.23%) | | |
| occurrences (all) | 37 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 11 / 62 (17.74%) | | |
| occurrences (all) | 11 | | |
| Vomiting | | | |
| subjects affected / exposed | 11 / 62 (17.74%) | | |
| occurrences (all) | 15 | | |
| Anorectal discomfort | | | |
| subjects affected / exposed | 5 / 62 (8.06%) | | |
| occurrences (all) | 5 | | |
| Anal pruritus | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Haemorrhoids | | | |
| subjects affected / exposed | 6 / 62 (9.68%) | | |
| occurrences (all) | 6 | | |
| Dry mouth | | | |
| subjects affected / exposed | 7 / 62 (11.29%) | | |
| occurrences (all) | 7 | | |
| Dyspepsia | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 5 | | |
| Proctalgia | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Constipation | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 5 / 62 (8.06%) | | |
| occurrences (all) | 6 | | |

| | | | |
|----------------------------------|----------------|--|--|
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Aphthous stomatitis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Flatulence | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Haematochezia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Abdominal distension | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Gingival bleeding | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Toothache | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|-----------------------------|----------------|--|--|
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Epigastric discomfort | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Glossodynia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Oral pain | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Proctitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Retching | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Abdominal pain lower | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Abdominal tenderness | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Anal fissure | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ascites | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Bowel movement irregularity | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Duodenal ulcer | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |

| | | | |
|------------------------------------|----------------|--|--|
| Eructation | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Faeces pale | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Frequent bowel movements | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Gastrointestinal motility disorder | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Glossitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyperchlorhydria | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Lip dry | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Lip pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oral discomfort | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|--|------------------|--|--|
| Perianal erythema | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sensitivity of teeth | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Steatorrhoea | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Swollen tongue | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tongue coated | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tongue disorder | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Tooth impacted | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Periportal oedema | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |
| Pruritus | | | |
| subjects affected / exposed | 24 / 62 (38.71%) | | |
| occurrences (all) | 25 | | |
| Rash | | | |
| subjects affected / exposed | 13 / 62 (20.97%) | | |
| occurrences (all) | 17 | | |
| Alopecia | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 7 / 62 (11.29%) | | |
| occurrences (all) | 7 | | |
| Dry skin | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Pruritus generalised | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Rash maculo-papular | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 4 | | |
| Rash papular | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Rash erythematous | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 2 | | |
| Dermatitis | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Rash generalised | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Swelling face | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Erythema | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 2 | | |
| Night sweats | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Psoriasis | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Eczema | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash macular | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin irritation | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Urticaria | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Drug eruption | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blister | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Drug reaction with eosinophilia and systemic symptoms | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hair growth abnormal | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hair texture abnormal | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|---|----------------|--|--|
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Purpura | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash follicular | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash vesicular | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Scab | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Seborrhoea | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Seborrhoeic dermatitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin burning sensation | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Skin exfoliation | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Stasis dermatitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Telangiectasia | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Renal and urinary disorders | | | |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dysuria | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 8 / 62 (12.90%) | | |
| occurrences (all) | 10 | | |
| Myalgia | | | |
| subjects affected / exposed | 11 / 62 (17.74%) | | |
| occurrences (all) | 12 | | |
| Back pain | | | |
| subjects affected / exposed | 4 / 62 (6.45%) | | |
| occurrences (all) | 4 | | |
| Muscle spasms | | | |

| | | | |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 3 | | |
| Joint swelling | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 2 | | |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Bone pain | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Neck pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Costochondritis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Joint stiffness | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Plantar fasciitis | | | |

| | | | |
|-----------------------------------|----------------|--|--|
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Spinal pain | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infections and infestations | | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 3 / 62 (4.84%) | | |
| occurrences (all) | 4 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 2 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear infection | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cystitis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Influenza | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 3 | | |

| | | | |
|-----------------------------|----------------|--|--|
| Skin infection | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Vulvovaginal candidiasis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Candida infection | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Dermatitis infected | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Folliculitis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Genital herpes | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gingivitis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Herpes pharyngitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Parotitis | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash pustular | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |

| | | | |
|------------------------------------|------------------|--|--|
| Rhinitis | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Scrotal abscess | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Tinea cruris | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vulvovaginal mycotic infection | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 10 / 62 (16.13%) | | |
| occurrences (all) | 12 | | |
| Dehydration | | | |
| subjects affected / exposed | 2 / 62 (3.23%) | | |
| occurrences (all) | 3 | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Abnormal loss of weight | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gout | | | |
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyperuricaemia | | | |

| | | | |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 62 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 62 (1.61%) | | |
| occurrences (all) | 1 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|----------------|---|
| 25 August 2011 | Following FDA recommendation, changed study design to randomized study of 2 treatment regimens. Subjects who have rapid viral response (RVR) and no permanent discontinuation of any study drug will be randomized 2:1 to T12/PR12 or T12/PR24 group. To reflect study design changes, title was changed to specify 2 treatment durations and include subjects with prior relapse. Revised the text for sample size and power, to account for the additional treatment arm. Added allowance for 2 interim analyses. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

| |
|---|
| The study was terminated early at the primary efficacy endpoint (SVR12), by the sponsor on 13 January 2014 due to a decision to modify the drug development plan. |
|---|

Notes: